reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
citrate → cis-aconitate → isocitrate → α-ketoglutarate → succinyl-CoA → succinate → fumarate → malate → oxaloacetate → citrate In this cycle, the enzyme isocitrate dehydrogenase 3 converts isocitrate (isocitrate has 4 isomers of which only the (−)-d-threo-isomer is the naturally occurring isomer in the citric acid cycle.) to α-ketoglutarate which in the next step is converted to succinyl-CoA by the oxoglutarate dehydrogenase complex of enzymes.
Clean road, rail, sea and air transport are fundamental goals of the EU, given its commitment to human rights for 'improvement of the quality of the environment', 'services of general economic interest', and the right to 'the benefits of scientific progress'. However, the pace of reform is slow compared to the urgency of reversing global heating. The Renewable Energy Directive 2018 article 25 requires that final energy consumption in transport in each member state is 'at least 14%' renewable by 2030. This is within the 2030 target for 32% "share of energy from renewable sources in the Union's gross final consumption of energy". In 2022, the EU promised to ban sale of new petrol and diesel vehicles only by 2035, enabling manufacturing corporations to profit from toxic emissions for another 13 years, though many member states have higher standards. There is not yet a plan for full rail electrification, or clean shipping or air travel, even where technology exists.
In human adult females, the primordial follicle is composed of a single oocyte surrounded by a layer of closely associated granulosa cells. In early stages of the ovarian cycle, the developing follicle acquires a layer of connective tissue and associated blood vessels. This covering is called the theca. As development of the secondary follicle progresses, granulosa cells proliferate to form the multilayered membrana granulosum. Over a period of months, the granulosa cells and thecal cells secrete follicular fluid (a mixture of hormones, enzymes, and anticoagulants) to nourish the maturing ovum. In tertiary follicles, the single-layered theca differentiates into a theca interna and theca externa. The theca interna contains glandular cells and many small blood vessels, while the theca externa is composed of dense connective tissue and larger blood vessels.
== Medical devices == A variety of medical devices are in use or under consideration for treatment of depression including devices that offer electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and cranial electrotherapy stimulation. The use of such devices in the United States requires approval by the U.S. Food and Drug Administration (FDA) after field trials. In 2010 an FDA advisory panel considered the question of how such field trials should be managed. Factors considered were whether drugs had been effective, how many different drugs had been tried, and what tolerance for suicides should be in field trials.
Sources: en.wikipedia.org
(2) The study of Raymond Damadian (New York Downstate Medical Center, 1971-1972): Inspired by Hazlewood and Chang's findings about cellular water relaxation time changes during muscle development, Damadian proposed that T1 is generally longer in tumors compared to normal tissues. He demonstrated this idea with a quick NMR measurement on rat tissues. Damadian also filed a patent in late 1972 for a full-body machine of using NMR to detect cancer. (3) The study of Paul Lauterbur (The State University of New York at Stony Brook, 1973): Lauterbur proposed to use a magnetic field gradient to conduct a 2-dimensional NMR scan. He called his method zeugmatography. For demonstration, he used CW NMR (not spin-echo) to image the proton spin density in an artificial sample consisting of two tubes of water. In the late 1970s, physicists Peter Mansfield at the University of Nottingham and Lauterbur developed MRI-related techniques, like the echo-planar imaging (EPI) technique. Raymond Damadian's work into nuclear magnetic resonance (NMR) has been incorporated into MRI, having built one of the first scanners. Advances in semiconductor technology were crucial to the development of practical MRI, which requires a large amount of computational power. This was made possible by the rapidly increasing number of transistors on a single integrated circuit chip. Mansfield and Lauterbur were awarded the 2003 Nobel Prize in Physiology or Medicine for their "discoveries concerning magnetic resonance imaging".
== Foreign relations == Throughout the period of its Unilateral Declaration of Independence (1965 to 1979), Rhodesia pursued a foreign policy of attempting to secure recognition as an independent country, and insisting that its political system would include 'gradual steps to majority rule.' Ardently anti-communist, Rhodesia tried to present itself to the West as a front-line state against communist expansion in Africa, to little avail. Rhodesia received little international recognition during its existence; recognition only occurred after elections in 1980 and a transition to majority rule. Rhodesia wished to retain its economic prosperity and also feared communist elements in the rebel forces, and thus felt their policy of a gradual progression to black majority rule was justified. However, the international community refused to accept this rationale, believing that their policies were perpetuating racism. This attitude was part of the larger decolonisation context, during which Western powers such as the United Kingdom, France, and Belgium hastened to grant independence to their colonies in Africa.
==== MeSH D12.776.377.715.085 – alpha-globulins ==== MeSH D12.776.377.715.085.050 – alpha 1-antichymotrypsin MeSH D12.776.377.715.085.085 – alpha 1-antitrypsin MeSH D12.776.377.715.085.100 – alpha-macroglobulins MeSH D12.776.377.715.085.118 – antiplasmin MeSH D12.776.377.715.085.125 – antithrombin iii MeSH D12.776.377.715.085.214 – ceruloplasmin MeSH D12.776.377.715.085.394 – haptoglobins MeSH D12.776.377.715.085.450 – heparin cofactor ii MeSH D12.776.377.715.085.640 – orosomucoid MeSH D12.776.377.715.085.740 – progesterone-binding globulin MeSH D12.776.377.715.085.750 – retinol-binding proteins MeSH D12.776.377.715.085.901 – transcortin
Public health advisories to prevent fentanyl misuse and fatal overdose have been issued by the US Centers for Disease Control and Prevention (CDC). An initial HAN Advisory, also known as a Health Alert Network Advisory ("provides vital, time-sensitive information for a specific incident or situation; warrants immediate action or attention by health officials, laboratorians, clinicians, and members of the public; and conveys the highest level of importance") was issued during October 2015. A subsequent HAN Alert was issued in July 2018, warning of rising numbers of deaths due to fentanyl abuse and mixing with non-opioids. A December 2020 HAN Advisory warned of:
=== Computing, environmental, and interdisciplinary research === The National Science Foundation funded the iPlant Collaborative in 2008 with a $50 million grant. In 2013, iPlant Collaborative received a $50 million renewal grant. Rebranded in late 2015 as "CyVerse", the collaborative cloud-based data management platform is moving beyond life sciences to provide cloud-computing access across all scientific disciplines. In June 2011, the university announced it would assume full ownership of the Biosphere 2 scientific research facility in Oracle, Arizona. Biosphere 2 was constructed by private developers (funded mainly by Texas businessman and philanthropist Ed Bass) with its first closed system experiment commencing in 1991. The university had been the official management partner of the facility for research purposes since 2007.
Sources: en.wikipedia.org
Antifungals, e.g. ketoconazole. Antibiotics, e.g. erythromycin, rifampicin. Ergot derivatives used to treat migraine or Parkinson's disease may cause an increase in blood pressure. Any potassium-depleting diuretics (medicines for eliminating water), e.g. thiazides. Carbamazepine and phenobarbital, medicines used to control fits or seizures. Herbal medicines that contain St. John's Wort.
=== Regulations === Because of the adverse effects of cadmium on the environment and human health, the supply and use of cadmium is restricted in Europe under the REACH Regulation. The EFSA Panel on Contaminants in the Food Chain specifies that 2.5 μg/kg body weight is a tolerable weekly intake for humans. The Joint FAO/WHO Expert Committee on Food Additives has declared 7 μg/kg body weight to be the provisional tolerable weekly intake level. The state of California requires a food label to carry a warning about potential exposure to cadmium on products such as cocoa powder. The European Commission has put in place the EU regulation (2019/1009) on fertilizing products (EU, 2019), adopted in June 2019 and fully applicable as of July 2022. It sets a Cd limit value in phosphate fertilizers to 60 mg kg−1 of P2O5. The U.S. Occupational Safety and Health Administration (OSHA) has set the permissible exposure limit (PEL) for cadmium at a time-weighted average (TWA) of 0.005 ppm. The National Institute for Occupational Safety and Health (NIOSH) has not set a recommended exposure limit (REL) and has designated cadmium as a known human carcinogen. The IDLH (immediately dangerous to life and health) level for cadmium is 9 mg/m3.
Some reach back even further as Wisconsin School historian Walter LaFeber in his study America, Russia, and the Cold War, first published in 1972, argued that the Cold War had its origins in 19th century conflicts between Russia and the United States over the opening of East Asia to American trade, markets and influence. LaFeber argued that the United States commitment at the close of World War II to ensuring a world in which every state was open to American influence and trade, underpinned many of the conflicts that triggered the beginning of the Cold War. Starting with Gar Alperovitz in his influential Atomic Diplomacy: Hiroshima and Potsdam (1965), revisionists have focused on the United States decision to use atomic weapons against Hiroshima and Nagasaki during the last days of World War II. In their belief, the nuclear bombing of Nagasaki and Hiroshima in effect started the Cold War. According to Alperovitz, the bombs were used not against an already-defeated Japan to win the war, but to intimidate the Soviets by signaling that the United States would use nuclear weapons to stop Soviet expansion, though they failed to do so. New Left historians Joyce and Gabriel Kolko's The Limits of Power: The World and U.S. Foreign Policy, 1945–1954 (1972) has also received considerable attention in the historiography on the Cold War. The Kolkos argued American policy was both reflexively anticommunist and counterrevolutionary.
The surface of the rough endoplasmic reticulum (often abbreviated RER or rough ER; also called granular endoplasmic reticulum) is studded with protein-manufacturing ribosomes giving it a "rough" appearance (hence its name). The binding site of the ribosome on the rough endoplasmic reticulum is the translocon. However, the ribosomes are not a stable part of this organelle's structure as they are constantly being bound and released from the membrane. A ribosome only binds to the RER once a specific protein-nucleic acid complex forms in the cytosol. This special complex forms when a free ribosome begins translating the mRNA of a protein destined for the secretory pathway. The first 5–30 amino acids polymerized encode a signal peptide, a molecular message that is recognized and bound by a signal recognition particle (SRP). Translation pauses and the ribosome complex binds to the RER translocon where translation continues with the nascent (new) protein forming into the RER lumen and/or membrane. The protein is processed in the ER lumen by an enzyme (a signal peptidase), which removes the signal peptide. Ribosomes at this point may be released back into the cytosol; however, non-translating ribosomes are also known to stay associated with translocons. The membrane of the rough endoplasmic reticulum is in the form of large double-membrane sheets that are located near, and continuous with, the outer layer of the nuclear envelope.
Amino acid N-carboxyanhydrides, also called Leuchs' anhydrides, are a family of heterocyclic organic compounds derived from amino acids. They are white, moisture-reactive solids. They have been evaluated for applications the field of biomaterials. NCAs are typically prepared by phosgenation of amino acids: They were first synthesized by Hermann Leuchs by heating an N-ethoxycarbonyl or N-methoxycarbonyl amino acid chloride in a vacuum at 50-70 °C: A moisture-tolerant route to unprotected NCAs employs epoxides as scavengers of hydrogen chloride. This synthesis of NCAs is sometimes called the Leuchs method. The relatively high temperatures necessary for this cyclization results in the decomposition of several NCAs. Of several improvements, one notable procedure involves treating an unprotected amino acid with phosgene or its trimer. NCAs are prone to hydrolysis to the parent amino acid: RCHNHC(O)OC(O) + H2O → H2NCH(R)CO2H + CO2 Some derivatives however tolerate water briefly. NCAs convert to homopolypeptides ( [N(H)CH(R)CO)]n) through ring-opening polymerization:
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.